Compare Freeport-McMoRan Inc (FCX) vs Smith & Nephew plc (SNN) Price & Performance

Freeport-McMoRan (FCX) trades at $71.87, down 0.97% on the day, with strong technical momentum indicated by bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected shortly. FCX maintains solid profitability with 11.38% net margin and 15.37% ROE, supported by robust operational cash flow of $5.61 billion in 2025. Recent news highlights copper's strategic importance for AI infrastructure, positioning FCX to benefit from long-term demand trends.

FCX presents a compelling opportunity with analyst consensus at Buy (61%) and $73.27 price target, offering 2% upside. The company's expansion projects and copper's AI-driven demand create growth potential, though rising production costs and ongoing legal investigation pose risks. Institutional sentiment remains positive given FCX's market leadership and favorable commodity outlook.

Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.

The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.